Publications by authors named "S Jinnouchi"
Objective: This multicenter, phase II clinical trial evaluated the diagnostic performance of 18F-fluciclovine, a novel amino acid for positron-emission tomography (PET), for detection of small lymph node metastases with short-axis diameters of 5-10 mm in patients with prostate cancer.
Methods: Patients with prostate cancer were eligible after screening of laboratory tests and pelvic contrast-enhanced computed tomography (CT). Pelvic region 18F-fluciclovine PET/CT was then acquired within 28 days and dissection of regional lymph nodes was performed within 60 days of pelvic contrast-enhanced CT.
Article Synopsis
- The study assessed the effectiveness of the FDG-PET cancer screening program for early breast cancer detection in asymptomatic women in Japan from 2006 to 2009.
- Out of 62,054 women screened, 161 cases of breast cancer were confirmed from 473 possible cases, showing FDG-PET's sensitivity at 83.9% and a positive predictive value (PPV) of 41.7%.
- The findings suggest that while FDG-PET is effective for early detection, combining it with mammography and ultrasound may enhance sensitivity but doesn't significantly improve PPV; most detected cancers were at early stages (0 or I).
Article Synopsis
- The study evaluates the effectiveness of FDG-PET cancer screening in identifying thyroid cancer in asymptomatic individuals in Japan, analyzing data from 153,775 participants.
- Out of 1,308 potential thyroid cancer cases detected, 353 were confirmed, demonstrating the FDG-PET's sensitivity of 90.7% and positive predictive value of 29.5%.
- The results suggest that combining FDG-PET with thyroid ultrasonography enhances cancer detection rates, particularly identifying many cases at an early stage while also catching some advanced tumors.
Objectives: The aim of this study was to analyze detection rates and effectiveness of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program for prostate cancer in Japan, which is defined as a cancer-screening program for subjects without known cancer. It contains FDG-PET aimed at detection of cancer at an early stage with or without additional screening tests such as prostate-specific antigen (PSA) and magnetic resonance imaging (MRI).
Methods: A total of 92,255 asymptomatic men underwent the FDG-PET cancer screening program.